John Kotter, MD
Cardiovascular Disease · Lexington, KYNPI 1245464148
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,507 of the $2,130 with a category attached, or 70.8%. 5 manufacturers reported payments, led by Boston Scientific at 58.5% of the total. That places this record below the midpoint for cardiovascular disease clinicians in KY, where the typical reported total is $2,503.
Across 17 payments — averaging $125.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$1K
- Ancora Heart, Inc.$714
- Abbott$74
- Misonix Inc$71
- Novartis$25
Across 37 payments — averaging $6446.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$138K
- AstraZeneca$43K
- Boehringer Ingelheim International GmbH$25K
- Boehringer Ingelheim Pharma GmbH & Co.kg$16K
- Medtronic$11K
- Abbott$5K
What the payments were for
- Speaking & faculty fees$713%
- Travel & lodging$1,50771%
- Food & beverage$55126%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 8 | $1,247 |
| Ancora Heart, Inc. | 6 | $714 |
| Abbott | 1 | $74 |
| Misonix Inc | 1 | $71 |
| Novartis | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,130 in reported general payments places this provider in the 45th percentile of 258 cardiovascular disease providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $21,512 |
| Metoprolol Succinate | 16 | $162 |
| Atorvastatin Calcium | 13 | $148 |
| Spironolactone | 20 | $101 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Lexington
- William SkinnerLexington$312K
- David MoliternoLexington$115K
- Andrew LeventhalLexington$43K
- John GurleyLexington$21K
- Suresh SharmaLexington$15K
- James CragerLexington$12K
- Kevin ScullyLexington$9K
- Nathan KustererLexington$8K
- Amir PirachaLouisville$530K
- Dinesh KalraLouisville$316K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.